Boston Scientific (NYSE:BSX)
- Number of Upgrades
- 19 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 19 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $85.38 (2.0% Upside)
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read More
Recent Analyst Ratings
Recent Recommendations for Boston Scientific:
- Boston Scientific Co. (NYSE: BSX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating. (9/13/2024)
- Boston Scientific Co. (NYSE: BSX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating. (9/5/2024)
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Raymond James from $91.00 to $94.00. They now have a "strong-buy" rating on the stock. (9/4/2024)
- Boston Scientific Co. (NYSE: BSX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating. (8/28/2024)
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Barclays PLC from $78.00 to $86.00. They now have an "overweight" rating on the stock. (8/22/2024)
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Citigroup Inc. from $90.00 to $92.00. They now have a "buy" rating on the stock. (8/22/2024)
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Raymond James from $85.00 to $91.00. They now have a "strong-buy" rating on the stock. (7/25/2024)
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at JPMorgan Chase & Co. from $82.00 to $85.00. They now have an "overweight" rating on the stock. (7/25/2024)
- Boston Scientific Co. (NYSE: BSX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $85.00 price target on the stock. (7/25/2024)
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Robert W. Baird from $90.00 to $91.00. They now have an "outperform" rating on the stock. (7/25/2024)
